鼻咽癌放疗相关第二原发口腔癌的研究进展

摘要/Abstract

摘要： 放疗作为鼻咽癌（NPC）的主要治疗方法已使其得到有效控制，但由于与鼻咽部解剖位置临近，放疗引起的口腔并发症非常普遍，口腔第二原发癌(SPM)已成为导致NPC患者最终生存率低的重要原因。SPM的发病机制尚未完全明确，患者预后较差，对其的研究仍在探索中。

关键词: 鼻咽肿瘤, 放射疗法, 口腔, 第二原发癌

Abstract: Radiotherapy is the primary treatment modality for nasopharyngeal carcinoma（NPC） which can effectively control the disease. Oral cavity, anatomically near nasopharyngeal region is the main area for the occurrence of complication of radiotherapy. Second primary malignancy （SPM） in oral cavity is an important factor interferencing NPC patients survival rate. The etiology of oral SPM is unclear and, the prognosis is poor. The research of it is still in exploration.

Key words: Nasopharyngeal neoplasms, Radiotherapy, Mouth, Second primary malignancies

赵楠, 吴桐, 程斌. 鼻咽癌放疗相关第二原发口腔癌的研究进展[J]. 国际肿瘤学杂志, 2016, 43(2): 145-.

ZHAO Nan, WU Tong, CHENG Bin. Research advances on second primary malignancies of oral cavity following radiotherapy for nasopharyngeal carcinoma[J]. Journal of International Oncology, 2016, 43(2): 145-.

参考文献

［1］ Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012［J］. Int J Cancer, 2015, 136(5): E359386. DOI:10.1002/ijc.29210. ［2］ Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human development index (20082030): a populationbased study［J］. Lancet Oncol, 2012, 13(8): 790801. DOI:10.1016/S14702045(12)702115. ［3］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. DOI:10.3322/caac.20107. ［4］ Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China［J］. Chin J Cancer, 2011, 30(2): 114119. ［5］ Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial［J］. Lancet Oncol, 2012, 13(2): 163171. DOI:10.1016/S14702045(11)703205. ［6］ Macready N. Looking treatment complications in the mouth［J］. J Natl Cancer Inst, 2013, 105(2): 7677. DOI:10.1093/jnci/djs643. ［7］ Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a metaanalysis of the phase Ⅲ randomized trials［J］. BMC Cancer, 2010, 10(1): 558. DOI:10.1186/1471240710558. ［8］黄引芳, 傅深, 章青, 等. 白细胞介素11预防和治疗头颈部肿瘤放疗导致口腔黏膜反应的疗效观察［J］. 国际肿瘤学杂志, 2010, 37(9): 710712 ［9］ Xi M, Liu SL, Zhao L, et al. Prognostic factors and survival in patients with radiationrelated second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma［J］. PLoS One, 2013, 8(12): e84586. DOI:10.1371/journal.pone.0084586. ［10］ Song M, Zhuang SM, Chen SW, et al. Survival study and treatment strategy for second primary tumors in the oral cavity in patients with nasopharyngeal carcinoma after definitive radiation［J］. Head Neck, 2012, 34(11): 15511555. DOI:10.1002/hed.21959. ［11］ Kong L, Lu JJ, Hu C, et al. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy［J］. Cancer, 2006, 107(6): 12871293. DOI:10.1002/cncr.22119. ［12］ Wang CC, Chen ML, Hsu KH, et al. Second malignant tumors in patients with nasopharyngeal carcinoma and their association with EpsteinBarr virus［J］. Int J Cancer, 2000, 87(2): 228231. ［13］ Chan JY, Gooi Z, Mydlarz WK, et al. Risk of second primary malignancy after nasopharyngeal carcinoma in the United States: a populationbased study［J］. Head Neck, 2015, in press. DOI:10.1002/hed.24173. ［14］ Lin C, Lin SW, Weng SF, et al. Risk of second primary malignancies after nasopharyngeal carcinoma: a populationbased cohort study in Taiwan［J］. Head Neck, 2014, 36(2): 209214. DOI:10.1002/hed.23281. ［15］ Chen MC, Feng IJ, Lu CH, et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a populationbased study in Taiwan over a 25year period (19792003)［J］. Ann Oncol, 2008, 19(6): 11801186. DOI:10.1093/annonc/mdn003. ［16］ Sun C, Hu Z, Zhong Z, et al. Clinical and prognostic analysis of second primary squamous cell carcinoma of the tongue after radiotherapy for nasopharyngeal carcinoma［J］. Br J Oral Maxillofac Surg, 2014, 52(8): 715720. DOI:10.1016/j.bjoms.2014.06.015. ［17］ Teo PM, Chan AT, Leung SF, et al. Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinomathe possibility of radiation carcinogenesis［J］. Eur J Cancer, 1999, 35(2): 219225. ［18］孙传政, 陈福进, 曾宗渊, 等. 第一原发性舌癌和鼻咽癌放疗后第二原发性舌癌的比较分析［J］. 中华肿瘤杂志, 2006, 28(12): 938941 ［19］ Cha C, Antonescu CR, Quan ML, et al. Longterm results with resection of radiationinduced soft tissue sarcomas［J］. Ann Surg, 2004, 239(6): 903909. ［20］ Robbins KT, Samant S, Vieira F, et al. Presurgical cytoreduction of oral cancer using intraarterial cisplatin and limited concomitant radiation therapy (NeoRADPLAT)［J］. Arch Otolaryngol Head Neck Surg, 2004, 130(1): 2832. DOI:10.1001/archotol.130.1.28. ［21］ Rennemo E, Ztterstrm U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2 063 cases［J］. Laryngoscope, 2008, 118(8): 13501356. DOI:10.1097/MLG.0b013e318172ef9a. ［22］叶玲, 刘晓清, 周琦超, 等. 个体化口腔支架在鼻咽癌患者调强放疗中应用的剂量分析［J］. 中山大学学报:医学科学版, 2014, 35(1): 7479 ［23］ Berrington De Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US Seer cancer registries［J］. Lancet Oncol, 2011, 12(4): 353360. DOI:10.1016/S14702045(11)700614. ［24］ Goggins WB, Yu IT, Tse LA, et al. Risk of second primary malignancies following nasopharyngeal carcinoma in Hong Kong［J］. Cancer Causes Control, 2010, 21(9): 14611466. DOI:10.1007/s105520109574x. ［25］ Scélo G, Boffetta P, Corbex M, et al. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries［J］. Cancer Causes Control, 2007, 18(3): 269278. DOI:10.1007/s105520060101z. ［26］ Lv P, Wang Y, Ma J, et al. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair［J］. Oncotarget, 2014, 5(17): 75127524.

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[6]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[7]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[8]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[9]	崔腾璐, 孙鹏飞. 鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.
[10]	顾安琴, 龙金华, 金风. 鼻咽癌免疫治疗的临床研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 299-303.
[11]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[12]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[13]	李进芝, 赵彪, 文晓博, 张明, 袁美芳, 孙梦真, 蒲琴, 杨毅. Monaco系统计算网格尺寸对T₄期鼻咽癌的剂量学影响[J]. 国际肿瘤学杂志, 2023, 50(11): 641-649.
[14]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[15]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇. 重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.